Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Seliger, Barbara ^a   Handke, Diana ^a   Schabel, Elisabeth ^a   Bukur, Juergen ^a   Lichtenfels, Rudolf ^a   Dammann, Reinhard ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; UBIQUITIN THIOLESTERASE; UBIQUITIN THIOLESTERASE I; UNCLASSIFIED DRUG; ENZYME INHIBITOR; TUMOR MARKER; UCHL1 PROTEIN, HUMAN;

AMPLICON; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KIDNEY TUMOR; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; KIDNEY NEOPLASMS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN THIOLESTERASE;

EID: 71149090166     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-90     Document Type: Article

References (56)

1. Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 1998, 95:2727-2730. 10.1073/pnas.95.6.2727, 34259, 9501156.
2. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989, 246:670-673. 10.1126/science.2530630, 2530630.
3. Larsen CN, Krantz BA, Wilkinson KD. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochem 1998, 37:3358-3368.
4. Pickart CM, Rose IA. Ubiquitin carboxyl-terminal hydrolase acts on ubiquitin carboxyl-terminal amides. J Biol Chem 1985, 260:7903-7910.
5. Eytan E, Armon T, Heller H, Beck S, Hershko A. Ubiquitin C-terminal hydrolase activity associated with the 26 S protease complex. J Biol Chem 1993, 268:4668-4674.
6. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111:209-218. 10.1016/S0092-8674(02)01012-7, 12408865.
7. Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. SeminCell Dev Biol 2000, 11:141-148.
8. Harada T, Harada C, Wang YL, Osaka H, Amanai K, Tanaka K, Takizawa S, Setsuie R, Sakurai M, Sato Y, Noda M, Wada K. Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury in vivo. Am J Pathol 2004, 164:59-64. 1602242, 14695319.
9. Kwon J, Wang YL, Setsuie R, Sekiguchi S, Sakurai M, Sato Y, Lee WW, Ishii Y, Kyuwa S, Noda M, Wada K, Yoshikawa Y. Developmental regulation of ubiquitin C-terminal hydrolase isozyme expression during spermatogenesis in mice. Biol Reprod 2004, 71:515-521. 10.1095/biolreprod.104.027565, 15084487.
10. Diomedi-Camassei F, Rava L, Lerut E, Callea F, Van Damme B. Protein gene product 9.5 and ubiquitin are expressed in metabolically active epithelial cells of normal and pathologic human kidney. Nephrol Dial Transplant 2005, 20:2714-2719. 10.1093/ndt/gfi124, 16188900.
11. Shirato I, Asanuma K, Takeda Y, Hayashi K, Tomino Y. Protein gene product 9.5 is selectively localized in parietal epithelial cells of Bowman's capsule in the rat kidney. J Am Soc Nephrol 2000, 11:2381-2386.
12. Tezel E, Hibi K, Nagasaka T, Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000, 6:4764-4767.
13. Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A. PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology 2003, 50:1278-1280.
14. Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, Li H, Cheng YY, Röcken C, Ebert MP, Chan AT, Sung JJ. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 2008, 48:505-518.
15. al-Katib AM, Mohammad RM, Maki A, Smith MR. Induced expression of a ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia. Cell Growth Differ 1995, 6:211-217.
16. Hibi K, Liu Q, Beaudry GA, Madden SL, Westra WH, Wehage SL, Yang SC, Heitmiller RF, Bertelsen AH, Sidransky D, Jen J. Serial analysis of gene expression in non-small cell lung cancer. Cancer Res 1998, 58:5690-5694.
17. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 1999, 155:711-715. 1866887, 10487828.
18. Otsuki T, Yata K, Takata-Tomokuni A, Hyodoh F, Miura Y, Sakaguchi H, Hatayama T, Hatada S, Tsujioka T, Sato Y, Murakami H, Sadahira Y, Sugihara T. Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. Br J Haematol 2004, 127:292-298. 10.1111/j.1365-2141.2004.05205.x, 15491288.
19. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002, 8:192-195.
20. Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Nakata Y, Kuma K, Amino N. PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma. Eur J Cancer 2004, 40:614-618. 10.1016/j.ejca.2003.11.016, 14962731.
21. Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S, Lichtenfels R. Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res 2007, 13:27-37. 10.1158/1078-0432.CCR-06-0824, 17200335.
22. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruine AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 2008, 1785:133-155.
23. Brena RM, Huang TH, Plass C. Quantitative assessment of DNA methylation: Potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med 2006, 84:365-377. 10.1007/s00109-005-0034-0, 16416310.
24. Doerfler W. De novo methylation, long-term promoter silencing, methylation patterns in the human genome, and consequences of foreign DNA insertion. Curr Top Microbiol Immunol 2006, 301:125-175. full_text, 16570847.
25. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054. 10.1056/NEJMra023075, 14627790.
26. Lesche R, Eckhardt F. DNA methylation markers: a versatile diagnostic tool for routine clinical use. Curr Opin Mol Ther 2007, 9:222-230.
27. Ramachandran K, Soloway MS, Singal R, Manoharan M. The emerging role of epigenetics in urological cancers. Can J Urol 2007, 14:3535-3541.
28. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447:433-440. 10.1038/nature05919, 17522677.
29. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome--components and functional correlates. Genes Dev 2006, 20:3215-3231. 10.1101/gad.1464906, 17158741.
30. Bittencourt Rosas SL, Caballero OL, Dong SM, da Costa Carvalho Mda G, Sidransky D, Jen J. Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett 2001, 170:73-79. 10.1016/S0304-3835(01)00449-9, 11448537.
31. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim MS, Osada M, Mori M, Sidransky D. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005, 65:4963-4968. 10.1158/0008-5472.CAN-04-3923, 15930319.
32. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003, 63:3735-3742.
33. Yamashita K, Park HL, Kim MS, Osada M, Tokumaru Y, Inoue H, Mori M, Sidransky D. PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res 2006, 66:3921-3927. 10.1158/0008-5472.CAN-05-1511, 16585221.
34. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, Ushijima T. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 2006, 119:1338-1344. 10.1002/ijc.22025, 16642472.
35. Kumagai T, Akagi T, Desmond JC, Kawamata N, Gery S, Imai Y, Song JH, Gui D, Said J, Koeffler HP. Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 2009, 124:827-833. 10.1002/ijc.23994, 19035457.
36. Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Itesako T, Kawamoto K, Nishiyama K, Seki N, Nakagawa M. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol 2008, 180:343-351. 10.1016/j.juro.2008.02.044, 18499164.
37. Seliger B, Höhne A, Knuth A, Bernhard H, Ehring B, Tampé R, Huber C. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 1996, 2:1427-1433.
38. Seliger B, Hammers S, Höhne A, Zeidler R, Knuth A, Gerharz CD, Huber C. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res 1997, 3:573-578.
39. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000, 25:315-319. 10.1038/77083, 10888881.
40. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999, 59:67-70.
41. Jerónimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001, 93:1747-1752. 10.1093/jnci/93.22.1747, 11717336.
42. Usadel H, Brabender J, Danenberg KD, Jerónimo C, Harden S, Engles J, Danenberg PV, Yang S, Sidransky D. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002, 62:371-375.
43. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994, 91:9700-9704. 10.1073/pnas.91.21.9700, 44884, 7937876.
44. Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998, 77:448-455. 2151296, 9472642.
45. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005, 23:4776-4789. 10.1200/JCO.2005.05.081, 16034054.
46. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001, 61:7908-7912.
47. Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Kim HJ, Lee KJ. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 2009, 28:117-127. 10.1038/onc.2008.364, 18820707.
48. Wang WJ, Li OO, Xu JD, Cao XX, Li HX, Tang F, Chen O, Yang JM, Xu ZD, Liu XP. Over-expression of ubiquitin carboxy terminal Hydrolase-L1 induces apoptosis in breast cancer cells. Int J Oncol 2008, 33:1037-1045. 2628585, 18949367.
49. Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y, Hoque MO, Westra WH, Califano JA, Sidransky D. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004, 64:5982-5987. 10.1158/0008-5472.CAN-04-0993, 15342377.
50. Lee YM, Lee JY, Kim MJ, Bae HI, Park JY, Kim SG, Kim DS. Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci 2006, 97:1205-1210. 10.1111/j.1349-7006.2006.00320.x, 16965602.
51. Mizukami H, Shirahata A, Goto T, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K. PGP9.5 methylation as a marker for metastatic colorectal cancer. Anticancer Res 2008, 28:2697-2700.
52. Ishibashi Y, Hanyu N, Suzuki Y, Yanai S, Tashiro K, Usuba T, Iwabuchi S, Takahashi T, Takada K, Ohkawa K, Urashima M, Yanaga K. Quantitative analysis of free ubiquitin and multi-ubiquitin chain in colorectal cancer. Cancer Lett 2004, 211:111-117. 10.1016/j.canlet.2004.01.028, 15194223.
53. Caballero OL, Resto V, Patturajan M, Meerzaman D, Guo MZ, Engles J, Yochem R, Ratovitski E, Sidransky D, Jen J. Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1). Oncogene 2002, 21:3003-3010. 10.1038/sj.onc.1205390, 12082530.
54. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpré P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003, 9:2912-2919.
55. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003, 1646:21-31.
56. Seliger B, Lichtenfels R, Kellner R. Detection of renal cell carcinoma-associated markers via proteome- and other 'ome'-based analyses. Brief Funct Genomic Proteomic 2003, 2:194-212. 10.1093/bfgp/2.3.194, 15239923.